Elizaveta Prosekina

Mrs. Elizaveta Prosekina

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Pathology - Research and Practice
Verified
Journal Article
Closed access
NANatalia Avdonkina
Natalia Avdonkina
ADA.B. Danilova
A.B. Danilova
VMV.A. Misyurin
V.A. Misyurin
EPElizaveta Prosekina
Elizaveta Prosekina
DGD.V. Girdyuk
D.V. Girdyuk
IBI.A. Baldueva
I.A. Baldueva

9 August 2024 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
KKKirill Kirgizov
Kirill Kirgizov
EPElizaveta Prosekina
Elizaveta Prosekina
ORO. M. Romantsova
O. M. Romantsova
TGT. V. Gorbunova
T. V. Gorbunova
Introduction. Tumor-associated gangliosides are overexpressed on a large number of tumors. The ratio of the amount of gangliosides varies from one type of tumor to another. Tissue restriction of GD2 expression in normal cells and its presence in a wide range of human tumor diseases has increased the relevance of GD2 as a target for immunooncology drugs.The aim of the study was to improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated and bone sarcomas) by incorporating targeted immunotherapeutic options (passive immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.The primary objective of the study was to analyze the efficacy of tandem use of antiGD2 MA and 2+ line chemotherapy on survival. Secondary targets were overall response rate (complete remission (CR) + partial remission (PR)), tumor control rate (CR + PR + stabilization), duration of response, and immune-associated adverse events.Materials and methods. The clinical study protocol was initiated at the Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia and approved by the local ethics committee No. 8 of 21.05.2021. On the basis of a signed memorandum of cooperation, the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia.The study is prospective. It is planned to evaluate the efficacy and safety of using antiGD2 MA and 2+ line chemotherapy at the investigator's choice in patients under 18 years of age with bone, soft tissue and undifferentiated sarcomas with positive GD2 expression and disease progression/recurrence on/after the 1st line of polychemotherapy.This study screened 40 patients to randomize 10 patients. In the future, an additional set of patients is planned.Conclusion. Based on the results obtained, the efficacy and safety of using a combination of antiGD2 immunotherapy and 2+ line chemotherapy in patients under 18 years of age with refractory and recurrent forms of bone and soft-tissue GD2-positive sarcomas will be concluded.

19 January 2025 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
KKKirill Kirgizov
Kirill Kirgizov
EPElizaveta Prosekina
Elizaveta Prosekina
ORO. M. Romantsova
O. M. Romantsova
NMN. V. Matinyan
N. V. Matinyan
Background. In the literature, information on the overexpression of disialoganglioside GD2 on the cells of malignant neoplasms is not uncommon. In this regard, this marker should be considered as a tumor-associated antigen, which may be a target on the cell surface in patients with poor prognosis.The aim of the study – improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated (unSA) and bone sarcomas) by incorporating targeted immunotherapeutic options (immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.Materials and methods. Ten patients with GD2-positive relapsed/refractory soft tissue sarcomas (STS, n = 4), osteosarcomas (OS, n = 2), Ewingʼs sarcomas (ES, n = 4) and unSA (n = 1) were included in the study. The gender ratio was 2.3:1 (boys:girls). The mean age at the time of inclusion in the study was 12 ± 2 years. The most of all patients (80 %) had a status of “primary resistant disease”. GD2 quantitative expression level was 29 ± 11 % (0.9 to 85 %). Patients were represented by deeply pretreated patients who received 8 to 25 cycles of 2+ line chemotherapy (mean 13). A total of 7 patients completed the full reinduction treatment (6 cycles of chemoimmunotherapy). All patients received anti-GD2 MA 100 mg/m2 as an intravenous 5-day infusion every 4 weeks, and treatment was continued until disease progression or 6 cycles. Fifty-two cycles of immunotherapy were performed.Results. Pain syndrome was the most frequently diagnosed (after 16 cycles, or in 30.7 % of cases); 5 (9.6 %) cycles each were accompanied by diarrhea, cytokine release syndrome, and increased capillary permeability syndrome. The immediate results varied according to the histological subtype of the tumor. The overall objective response rate was 43 % (3/7): 2 patients achieved complete remission (CR) and one achieved partial remission (PR). The disease control rate (CR + PR + stable) was 86 % (6/7). The clinical response rate 6 months after completion of chemoimmunotherapy ranged from 0 % (2/2) in ES to 50 % (1/2) in OS. In 43 % (3/7) of evaluable patients, disease progression was diagnosed after a mean of 5 months. At follow-up after 12 and 24 months, CR persisted in all patients with STS (100 %). Progression-free survival (PFS) in patients with STS at 6, 12 and 24 months was 100 % (PFS6, PFS12, PFS24, respectively). PFS6 in OS and ES patients was 100 % and 50 %, respectively, gradually decreasing to 0 %. The study revealed a very strong positive straight-line positive functional correlation between quantitative GD2 expression and progression-free survival (r = 0.971, p = 0.00006).Conclusion. Passive immunotherapy with monoclonal antibodies is a safe treatment method without severe immune-related adverse reactions. Patient follow-up and evaluation of the efficacy and safety of the drug after the end of the therapy plan continues until today, which allows a more detailed and objective evaluation of the results of immunotherapy according to the purpose of the study.

12 February 2025 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
EPElizaveta Prosekina
Elizaveta Prosekina
VSV.A. Shapkina
V.A. Shapkina
AKA.E. Karpov
A.E. Karpov
EFE.YU. Fedorutseva
E.YU. Fedorutseva
AAA.S. Artemyeva
A.S. Artemyeva
Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) is an essential enzyme capable of degrading asymmetric dimethylarginine, which is an endogenous inhibitor of nitric oxide synthase. Increased expression of DDAH1 and subsequent increased NO production are associated with carcinogenesis. In particular, DDAH1 is involved in the creation of a vascular network by tumor cells, vasculogenic mimicry, which is closely associated with tumor progression and poor patient prognosis. This is the reason why DDAH1 may be a potential therapeutic target for the treatment of cancer.

15 January 2025 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
EPElizaveta Prosekina
Elizaveta Prosekina
VSV. A. Shapkina
V. A. Shapkina
AKA. E. Karpov
A. E. Karpov
EFE. Yu. Fedorutseva
E. Yu. Fedorutseva
AAA. S. Artemyeva
A. S. Artemyeva
ЕФЕ. Ю. Федоруцева
Е. Ю. Федоруцева
Vasculogenic mimicry is a unique process through which tumor cells imitate normal vascular endothelial cells to secure access to the blood flow. In this review, we consider molecular mechanisms underlying this phenomenon and its importance in the context of solid tumor development. We have analyzed survival strategies of tumor cells using vasculogenic mimicry and described potential therapeutic approaches aimed at tumor growth and metastasis suppression. Highlighting the methods of histological and molecular identification of vasculogenic mimicry promotes better understanding of this phenomenon and its early diagnosis. The review focuses on the necessity of further research in the area of vasculogenic mimicry to conceptualize mechanisms underlying carcinogenesis. We have analyzed 109 articles from the leading biomedical databases including SciVerse Scopus, PubMed, Web of Science and RSCI (Russian Science Citation Index) which allowed us to summarize current scientific data and identify the key trends in the area of molecular oncology.

25 December 2025 in Supportive Therapy in Oncology
Verified
Journal Article
Open access
PDF file
AKAlika A. Kulyova
Alika A. Kulyova
SKSvetlana A. Kulyova
Svetlana A. Kulyova
RKRina I. Khabarova
Rina I. Khabarova
ESEvgeniy M. Senchurov
Evgeniy M. Senchurov
EMElena A. Mikhailova
Elena A. Mikhailova
TVTatiana L. Vershinina
Tatiana L. Vershinina
Immunotherapy is one of the most effective methods of cancer therapy. There are five main groups of immunotherapy, including treatment with chimeric antigen receptor T cells, checkpoint inhibitors, anticancer vaccines, antibody-based targeted therapies, and oncolytic viruses. On the adult cohort of patients, immunotherapy has been proven to increase the survival rate of patients with cancer. At the same time, in some patients, it can cause an immune-mediated damage and contribute to unfavorable heart immune modulation and heart failure. Immunotherapy can target many components of the cardiovascular system, including the myocardium, blood vessels, electrical wiring, and the pericardium. Activated T lymphocytes (CD4 + and CD8 + T cells) penetrate the heart tissue and skeletal targets, which leads to local inflammation and damage. Additional theoretical mechanisms for side effects include autoantibody recognition of self-antigens and T cell-mediated damage to cardiomyocytes and stressed endothelial cells. After treatment with T cells, the level of proinflammatory cytokines may increase, which is often the cause of cytokine release syndrome, the occurrence of which is considered a “targeted, non-neoplastic” effect. Proinflammatory cytokines can have negative cytotoxic effects on cardiomyocytes, resulting in reduced myocardial contractility, cardiomyopathy, and hypotension. This review presents a clinical case of cardiotoxicity due to the use of antiGD2 monoclonal antibodies in a child with a refractory form of osteosarcoma.